INVESTOR ALERT: Investigation of The Medicines Company Announced by Law Offices of Howard G. Smith
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of The Medicines Company (NASDAQ:MDCO) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by The Medicines Company concerning its operations and financial prospects.
The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company’s products include anticoagulants and treatments for blood pressure control and other cardiovascular indications. The investigation is related to allegations that: (a) the company issued materially misleading statements concerning the efficacy of its drug candidate Cangrelor, for preventing blood clots during angioplasty and stenting procedures, when compared to clopidogrel – a competing, FDA-approved drug; and (b) the company failed to disclose that the CHAMPION clinical trials of Cangrelor were unethically and inappropriately administered.
On February 13, 2014, the price of The Medicines Company shares dropped more than 11% after the company announced that the Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee voted against approval of Cangrelor for patients undergoing certain cardiac procedures.
If you purchased The Medicines Company securities between February 20, 2013 and February 12, 2014, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.